These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Raising the safety bar--the FDA's coxib meeting. Okie S N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221 [No Abstract] [Full Text] [Related]
3. The withdrawal of rofecoxib. Arellano FM Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):213-7. PubMed ID: 15724267 [No Abstract] [Full Text] [Related]
4. The lessons of Vioxx. Frazier KC N Engl J Med; 2005 Sep; 353(13):1420-1; author reply 1420-1. PubMed ID: 16192497 [No Abstract] [Full Text] [Related]
5. How to avoid another 'Vioxx'. Frantz S Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595 [No Abstract] [Full Text] [Related]
6. Learning the value of drugs--is rofecoxib a regulatory success story? Eisenberg RS N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222 [No Abstract] [Full Text] [Related]
7. Cyclooxygenase-2 inhibitors and cardiovascular risk. Smith ER Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124 [No Abstract] [Full Text] [Related]
8. Coxibs and cardiovascular risk. Allen MJ; McLean-Veysey P; Fleming I CMAJ; 2005 Oct; 173(8):853. PubMed ID: 16217098 [No Abstract] [Full Text] [Related]
9. [Insights and views about cardiovascular safety of COX2 inhibitors]. Wallentin L Lakartidningen; 2005 Feb 28-Mar 6; 102(9):666, 668, 671. PubMed ID: 15804041 [No Abstract] [Full Text] [Related]
10. What price pain relief? Hochman JS; Shah NR Circulation; 2006 Jun; 113(25):2868-70. PubMed ID: 16785335 [No Abstract] [Full Text] [Related]
11. Evaluating drug effects in the post-Vioxx world: there must be a better way. Avorn J Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873 [No Abstract] [Full Text] [Related]
12. [New evaluation by the EU approval committee. Benefits of cox-2 inhibitors outweigh possible risks (interview by Dr. Thomas Meissner)]. Brune K MMW Fortschr Med; 2004 Feb; 146(9):47. PubMed ID: 15352709 [No Abstract] [Full Text] [Related]
13. Lessons on prescribing and drug safety from the withdrawal of rofecoxib. Nelson M; Cicuttini F Aust Fam Physician; 2004 Dec; 33(12):965-6. PubMed ID: 15630913 [No Abstract] [Full Text] [Related]
14. [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart]. MMW Fortschr Med; 2003 Mar; 145(11):60. PubMed ID: 12688204 [No Abstract] [Full Text] [Related]
15. [Five turbulent years of coxibers. Where did the principle of caution go?]. HÃ¥kansson J; Rosenberg P Lakartidningen; 2005 May 2-15; 102(18-19):1432-4. PubMed ID: 15929426 [No Abstract] [Full Text] [Related]
16. New use approved for Vioxx. FDA Consum; 2002; 36(4):3. PubMed ID: 12184302 [No Abstract] [Full Text] [Related]
17. The Vioxx debacle revisited. Mohapatra PR; Janmeja AK Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909 [No Abstract] [Full Text] [Related]
18. Arthritis medicines and cardiovascular events--"house of coxibs". Topol EJ JAMA; 2005 Jan; 293(3):366-8. PubMed ID: 15623849 [No Abstract] [Full Text] [Related]
19. [Financial interests characterize published reports on coxiber. Whom can we rely on?]. HÃ¥kansson J Lakartidningen; 2002 Oct; 99(40):3930-1. PubMed ID: 12422746 [No Abstract] [Full Text] [Related]
20. The lessons of Vioxx--drug safety and sales. Waxman HA N Engl J Med; 2005 Jun; 352(25):2576-8. PubMed ID: 15972862 [No Abstract] [Full Text] [Related] [Next] [New Search]